UNSPSC 51293001: Nortriptyline

This classification denotes a tricyclic antidepressant with the molecular formula C19H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BL03SY4LXB, chemically known as 10,11-dihydro-n-methyl-5h-dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine but generally known as nortriptyline, which bears US NIH Compound Identifier 4543. European Medicines Agency schedules Nortriptyline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09380MIG.

UNSPSC 51293001 Nortriptyline is a Commodity code that describes a specific pharmaceutical product, but the recent state and local solicitations tagged under this code do not reflect nortriptyline procurement — instead they address broader pharmaceutical distribution, drug-deactivation systems, and pharmacy-benefit program design. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug-deactivation systems annually through competitive bidding; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products to be supplied through three authorized wholesalers to state and local government facilities across Minnesota and Oregon; and the Texas Health and Human Services Commission issued an RFI in April 2026 to explore direct-to-manufacturer prescription models outside traditional pharmacy benefit manager arrangements. The issuing bodies include county health departments, state purchasing consortia administering cooperative contracts, and state health agencies. The code shows little activity directly aligned with nortriptyline procurement itself.

Geographic spread centers on Florida, Minnesota, Oregon, and Texas based on the three identified opportunities. Seminole County's IFB reflects a single county's community health initiative with quarterly deliveries to a named location; MMCAP's RFP represents a multistate cooperative vehicle spanning Minnesota and Oregon with a response deadline of March 26, 2026; and Texas HHS's exploratory RFI, closing April 3, 2026, signals the state's intent to restructure how it sources pharmaceuticals. The mismatch between the code's nominal scope (nortriptyline, a specific tricyclic antidepressant) and the actual work being solicited (naloxone, multi-source generics, direct-manufacturer programs, and drug-deactivation systems) suggests this code does not reliably capture state and local procurement for nortriptyline itself or that the recent opportunities have been miscoded at the commodity level.